• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    12/19/22 4:31:56 PM ET
    $ALLR
    $AXLA
    $ENSC
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Metacrine (NASDAQ:MTCR) stock increased by 27.0% to $0.45 during Monday's after-market session. Today's trading volume for this security ended up closing at 742.5K shares, which is 251.9 percent of its average volume over the last 100 days. The company's market cap stands at $18.9 million.
    • Vallon Pharmaceuticals (NASDAQ:VLON) stock rose 21.28% to $0.38. Trading volume for this security closed at 1.4 million, accounting for 64.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.8 million.
    • Xenetic Biosciences (NASDAQ:XBIO) stock rose 17.81% to $0.33. The market value of their outstanding shares is at $5.0 million.
    • Precigen (NASDAQ:PGEN) stock increased by 8.72% to $1.62. The company's market cap stands at $337.2 million.
    • Renalytix (NASDAQ:RNLX) stock rose 8.28% to $1.7. The market value of their outstanding shares is at $63.6 million.
    • Otonomy (NASDAQ:OTIC) stock rose 8.02% to $0.12. Otonomy's trading volume hit 817.2K shares by close, accounting for 6.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $7.0 million.

    Losers

    • Soleno Therapeutics (NASDAQ:SLNO) stock decreased by 16.8% to $1.54 during Monday's after-market session. This security traded at a volume of 3.7 million shares come close, making up 5871.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $12.5 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares fell 12.78% to $0.31. Trading volume for this security closed at 487.3K, accounting for 106.2% of its average full-day volume over the last 100 days. The company's market cap stands at $3.1 million.
    • Axcella Health (NASDAQ:AXLA) shares fell 9.31% to $0.39. At the close, Axcella Health's trading volume reached 577.1K shares. This is 266.4% of its average volume over the last 100 days. The company's market cap stands at $28.6 million.
    • Coeptis Therapeutics (NASDAQ:COEP) stock fell 9.1% to $1.0. The company's market cap stands at $5.1 million.
    • Erasca (NASDAQ:ERAS) stock fell 7.93% to $4.1. The market value of their outstanding shares is at $551.7 million.
    • Ensysce Biosciences (NASDAQ:ENSC) shares fell 7.78% to $0.83. Today's trading volume for this security ended up closing at 871.3K shares, which is 86.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $AXLA
    $ENSC
    $ERAS

    CompanyDatePrice TargetRatingAnalyst
    Erasca Inc.
    $ERAS
    1/27/2026$16.00Outperform
    Mizuho
    Erasca Inc.
    $ERAS
    1/7/2026$5.00Overweight
    Piper Sandler
    Soleno Therapeutics Inc.
    $SLNO
    11/18/2025$75.00Outperform
    Wolfe Research
    Erasca Inc.
    $ERAS
    10/16/2025$4.00Buy
    Stifel
    Soleno Therapeutics Inc.
    $SLNO
    10/7/2025$125.00Buy
    Goldman
    Erasca Inc.
    $ERAS
    9/3/2025Buy → Underperform
    BofA Securities
    Soleno Therapeutics Inc.
    $SLNO
    8/20/2025$123.00Overweight
    Wells Fargo
    Erasca Inc.
    $ERAS
    8/18/2025$2.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ALLR
    $AXLA
    $ENSC
    $ERAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Thomasian Harry Jr.

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    3/20/26 7:35:07 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Tennant Phil

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    3/20/26 7:32:12 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sabzevari Helen

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    3/20/26 7:27:41 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AXLA
    $ENSC
    $ERAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

    Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028 SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for

    3/12/26 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

    GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in

    3/11/26 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

    Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015's promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will

    3/10/26 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AXLA
    $ENSC
    $ERAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho resumed coverage on Erasca with a new price target

    Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

    1/27/26 8:45:40 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Erasca with a new price target

    Piper Sandler initiated coverage of Erasca with a rating of Overweight and set a new price target of $5.00

    1/7/26 9:10:17 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Soleno Therapeutics with a new price target

    Wolfe Research initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $75.00

    11/18/25 8:27:59 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALLR
    $AXLA
    $ENSC
    $ERAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Shah Rutul R bought $6,800 worth of shares (2,000 units at $3.40), increasing direct ownership by 0.50% to 405,959 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/30/25 4:07:27 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Tennant Phil bought $21,480 worth of shares (6,000 units at $3.58), increasing direct ownership by 10% to 65,031 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/30/25 4:04:51 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Thomasian Harry Jr. bought $40,016 worth of shares (11,216 units at $3.57), increasing direct ownership by 2% to 468,626 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/26/25 5:01:54 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AXLA
    $ENSC
    $ERAS
    SEC Filings

    View All

    SEC Form 8-K filed by Ensysce Biosciences Inc.

    8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

    3/23/26 8:00:14 AM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Soleno Therapeutics Inc.

    8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

    3/16/26 9:28:28 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)

    3/13/26 8:00:27 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AXLA
    $ENSC
    $ERAS
    Financials

    Live finance-specific insights

    View All

    Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

    GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in

    3/11/26 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET

    REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, February 25, 2026Time:4:30 PM Eastern TimeUnited States:1-800-717-1738Internation

    2/11/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALLR
    $AXLA
    $ENSC
    $ERAS
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors

    REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno's Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven seats.    "I am very pleased to welcome Mark to the

    10/13/25 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

        TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period. Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other

    7/7/25 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AXLA
    $ENSC
    $ERAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 5:13:04 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care